Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) Versus the Standard of Care Imaging in the Diagnosis of Peritoneal Carcinomatosis
Overview
Authors
Affiliations
Objective: To compare positron emission tomography (PET)/magnetic resonance imaging (MRI) to the standard of care imaging (SCI) for the diagnosis of peritoneal carcinomatosis (PC) in primary abdominopelvic malignancies.
Summary Background Data: Identifying PC impacts prognosis and management of multiple cancer types.
Methods: Adult subjects were prospectively and consecutively enrolled from April 2019 to January 2021. Inclusion criteria were: 1) acquisition of whole-body contrast-enhanced (CE) 18F-fluorodeoxyglucose PET/MRI, 2) pathologically confirmed primary abdominopelvic malignancies. Exclusion criteria were: 1) greater than 4 weeks interval between SCI and PET/MRI, 2) unavailable follow-up. SCI consisted of whole-body CE PET/computed tomography (CT) with diagnostic quality CT, and/or CE-CT of the abdomen and pelvis, and/or CE-MRI of the abdomen±pelvis. If available, pathology or surgical findings served as the reference standard, otherwise, imaging followup was used. When SCI and PET/MRI results disagreed, medical records were checked for management changes. Follow-up data were collected until August 2021.
Results: One hundred sixty-four subjects were included, 85 (52%) were female, and the median age was 60 years (interquartile range 50-69). At a subject level, PET/MRI had higher sensitivity (0.97, 95% CI 0.86-1.00) than SCI (0.54, 95% CI 0.37-0.71), P < 0.001, without a difference in specificity, of 0.95 (95% CI 0.90-0.98) for PET/MRI and 0.98 (95% CI 0.93-1.00) for SCI, P ¼ 0.250. PET/MRI and SCI results disagreed in 19 cases. In 5/19 (26%) of the discordant cases, PET/MRI findings consistent with PC missed on SCI led to management changes.
Conclusion: PET/MRI improves detection of PC compared with SCI which frequently changes management.
Imaging of Peritoneal Surface Malignancies.
Caruso D, Sammartino P, Polici M, Masci G, Biacchi D, Zerunian M J Surg Oncol. 2024; 130(6):1203-1212.
PMID: 39508563 PMC: 11826024. DOI: 10.1002/jso.27979.
Imaging in malignant peritoneal neoplasms.
Srinivas Rao S, Ghosh S, Vardar B, Pandey A, Uma Baskaran N, Panwar S Abdom Radiol (NY). 2024; 50(3):1285-1306.
PMID: 39368001 DOI: 10.1007/s00261-024-04595-z.
Sathekge T, Boktor R, Berlangieri S, Lee S World J Nucl Med. 2024; 23(3):202-206.
PMID: 39170842 PMC: 11335380. DOI: 10.1055/s-0044-1778708.
Wilson M, Sorour S, Bao B, Murad M, Man V, Krill M Abdom Radiol (NY). 2024; 49(6):2135-2144.
PMID: 38523146 DOI: 10.1007/s00261-024-04195-x.
Imaging Evaluation of Peritoneal Metastasis: Current and Promising Techniques.
Fu C, Zhang B, Guo T, Li J Korean J Radiol. 2024; 25(1):86-102.
PMID: 38184772 PMC: 10788608. DOI: 10.3348/kjr.2023.0840.